Joseph DeSimone Image Map
Oct 112016
 

Cameron_BloomquistCongratulations to DeSimone lab graduate student, Cameron Bloomquist, who was selected as the winner of the Biomaterials category of the Triangle Student Research Competition (TSRC) on October 5th! Bloomquist’s poster, “Design and Fabrication of Biodegradable Drug-Eluting Devices Using the 3D Printing Technique Continuous Liquid Interface Production (CLIP),” focused on how design parameters—such as formulation of photopolymer resin, material properties of printed parts, and device geometry—influence drug release and degradation kinetics. A member of the DeSimone lab since 2013, Bloomquist is pursuing a Ph.D. in Pharmaceutical Sciences in UNC’s Eshelman School of Pharmacy.

Learn more about the TSRC

Learn more about CLIP

 October 11, 2016
Sep 162016
 

JMD_Duke Chronicle_Sept2016Since the early stages of Prof. DeSimone’s career as a professor at UNC and NC State, he has consistently stressed the importance of diversity in team problem-solving, emphasizing the role of diversity in the process of innovation. This was the subject of his September 14th speech at Duke University, as highlighted by The Chronicle, Duke University’s student newspaper.

Read the article in The Chronicle by Nidhila Masha

Learn more about DeSimone’s perspectives on diversity

 September 16, 2016
Aug 122016
 

Kapadia_2016Congratulations to Dr. Chintan Kapadia, who has been selected to receive an award for scientific engagement by the Gordon Research Conferences (GRC)! The award, for ‘most engaged person’ at the Drug Carriers in Medicine & Biology GRC in Waterville Valley, NH, recognizes Dr. Kapadia’s enthusiasm, engagement, and ability to generate highly stimulating discussions during the conference. For his efforts, he will receive a cash prize and copy of “Handbook of Immunological Properties of Engineered Nanomaterials” signed by renowned scientist, Dr. David Grainger.

Currently a postdoctoral researcher, Dr. Kapadia has been a member of the DeSimone lab since 2012. He recently graduated with his Ph.D. in Pharmaceutical Sciences after defending his dissertation, which focused on engineering PRINT nanoparticle-based subunit vaccines to induce an antitumor immune response.

 August 12, 2016
Jul 122016
 

tiniest doctors image cf desimone groupA new article published by the National Science & Technology Medals Foundation highlights the DeSimone lab’s research in the area of nanomedicine. Dr. DeSimone, a recent recipient of the National Medal of Technology & Innovation, is quoted in the article, which focuses broadly on how nanotechnology is revolutionizing the field of medicine.

Here in the lab, researchers are focused on using the Particle Replication in Nonwetting Templates (PRINT) technology to engineer nanoparticles for applications in oncology and vaccine design. Invented in the DeSimone lab, PRINT enables the fabrication of uniform nanoparticles with precise and independent control over attributes such as shape, size, composition, modulus, and surface chemistry.

Read the article by Allie Bidwell

 July 12, 2016
Jul 072016
 

stent_photo_2016The U.S. Food & Drug Administration (FDA) has approved the Absorb Bioresorbable Vascular System (BVS) for the treatment of coronary artery disease. It is the first and only fully dissolving, drug-eluting cardiac stent. In 2002, Dr. DeSimone made key contributions in developing materials for the stent, leading him to co-found Bioabsorbable Vascular Solutions (also known as BioStent) in partnership with Duke cardiologist, Richard Stack. Guidant acquired Bioabsorbable Vascular Solutions in 2003, and when Boston Scientific acquired Guidant, the stent franchise was sold to Abbott, which now markets the technology.

The dissolvable stent supports a patient’s clogged artery with the same strength as a traditional metal stent, but then uniquely dissolves completely over time after blood flow has been restored to the heart and the vessel is able to stay open on its own. This promotes healing by enabling a vessel to regain its natural flexibility without being inhibited by a permanent metal device.

The new device advanced rapidly through clinical trials worldwide, is now available in over 100 countries, and has been used in over 150,000 patients.

Read Abbott’s press release

 July 7, 2016